163 related articles for article (PubMed ID: 25193959)
1. Stringent patient selection improves outcomes in systemic light-chain amyloidosis after autologous stem cell transplantation in the upfront and relapsed setting.
Venner CP; Gillmore JD; Sachchithanantham S; Mahmood S; Lane T; Foard D; Roussel M; Rannigan L; Gibbs SDj; Pinney JH; Whelan CJ; Lachmann HJ; Hawkins PN; Wechalekar AD
Haematologica; 2014 Dec; 99(12):e260-3. PubMed ID: 25193959
[No Abstract] [Full Text] [Related]
2. Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.
Gertz MA; Lacy MQ; Dispenzieri A; Buadi FK; Dingli D; Hayman SR; Kumar SK; Leung N; Lust J; Rajkumar SV; Russell SJ; Suman VJ; Le-Rademacher JG; Hogan WJ
Cancer; 2016 Jul; 122(14):2197-205. PubMed ID: 27142462
[TBL] [Abstract][Full Text] [Related]
3. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
Warsame R; Bang SM; Kumar SK; Gertz MA; Lacy MQ; Buadi F; Dingli D; Hayman SR; Kapoor P; Kyle RA; Leung N; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Rajkumar SV; Dispenzieri A
Eur J Haematol; 2014 Jun; 92(6):485-90. PubMed ID: 24502602
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
[No Abstract] [Full Text] [Related]
6. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report.
Gertz MA; Lacy MQ; Dispenzieri A; Hayman SR; Kumar SK; Dingli D; Ansell SM; Gastineau DA; Inwards DJ; Johnston PB; Litzow MR; Micallef IN; Porrata LF; Leung N; Hogan WJ; Buadi FK
Leuk Lymphoma; 2010 Dec; 51(12):2181-7. PubMed ID: 20958232
[TBL] [Abstract][Full Text] [Related]
7. High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further?
Dimopoulos M; Kastritis E
Leuk Lymphoma; 2008 Jan; 49(1):4-5. PubMed ID: 18203000
[No Abstract] [Full Text] [Related]
8. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
Hazenberg BP; Croockewit A; van der Holt B; Zweegman S; Bos GM; Delforge M; Raymakers RA; Sonneveld P; Vellenga E; Wijermans PW; von dem Borne PA; van Oers MH; de Weerdt O; Spoelstra FM; Lokhorst HM;
Haematologica; 2015 May; 100(5):677-82. PubMed ID: 25661441
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
Tandon N; Sidana S; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Fonder AL; Hobbs MA; Hayman SR; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Am J Hematol; 2017 Jun; 92(6):549-554. PubMed ID: 28314084
[TBL] [Abstract][Full Text] [Related]
10. A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
Tan CR; Estrada-Merly N; Landau H; Lekakis L; Banerjee R; Mian H; Usmani SZ; Hanbali A; Lazarus HM; Kyle RA; Dholaria B; Bal S; Strouse C; Murthy HS; Wirk B; Nishihori T; Kumar S; Shah N; Qazilbash M; D'Souza A
Bone Marrow Transplant; 2022 Feb; 57(2):295-298. PubMed ID: 34802047
[No Abstract] [Full Text] [Related]
11. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
12. Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
Cordes S; Dispenzieri A; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Kumar SK; Hogan WJ; Gertz MA
Cancer; 2012 Dec; 118(24):6105-9. PubMed ID: 22707405
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic factors in light chain amyloidosis].
Jávorniczky NR; Bodó I; Masszi T; Mikala G
Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
[TBL] [Abstract][Full Text] [Related]
14. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
[TBL] [Abstract][Full Text] [Related]
15. Revisiting complete response in light chain amyloidosis.
Sidana S; Dispenzieri A; Murray DL; Go RS; Buadi FK; Lacy MQ; Gonsalves WI; Dingli D; Warsame R; Kourelis T; Muchtar E; Hayman SR; Kapoor P; Kyle RA; Leung N; Rajkumar SV; Gertz MA; Kumar SK
Leukemia; 2020 May; 34(5):1472-1475. PubMed ID: 31772296
[No Abstract] [Full Text] [Related]
16. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
17. Disease characteristics of diffuse large B-cell lymphoma predicting relapse and survival after autologous stem cell transplantation: A single institution experience.
Gaut D; Romero T; Oveisi D; Howell G; Schiller G
Hematol Oncol; 2020 Feb; 38(1):38-50. PubMed ID: 31674036
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of Autologous Hematopoietic Cell Transplantation Compared With Chemotherapy Consolidation Alone for Non-High-Risk Acute Myeloid Leukemia in First Complete Remission in a Minority-Rich Inner-City Cohort With Limited Access to Allografts.
Adrianzen Herrera D; Kornblum N; Derman O; Bachier-Rodriguez L; Sica RA; Shastri A; Janakiram M; Verma A; Braunschweig I; Mantzaris I
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):516-521. PubMed ID: 31227357
[TBL] [Abstract][Full Text] [Related]
19. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
20. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
